Dilek Kançağı, Derya

Loading...
Name Variants
Job Title
Doktor Öğretim
Email Address
derya.kancagi@fbu.edu.tr
Main Affiliation
Temel Eczacılık Bilimleri Bölümü
Status
Website
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID

Research Topics

Health SciencesLife Sciences
MedicineBiochemistry, Genetics and Molecular Biology
Infectious DiseasesGeneticsOncology
SARS-CoV-2 and COVID-19 Research
COVID-19 Clinical Research Studies
Virus-based gene therapy research
Viral gastroenteritis research and epidemiology
CAR-T cell therapy research

Sustainable Development Goals

SDG data is not available

Publication Collaboration

Affiliation Name Count
Acıbadem University 22
Acıbadem Adana Hospital 21
Kent Hastanesi 15
Yeditepe University 12
Üsküdar University 10
1 / 8
Data obtained from OpenAlex
Scholarly Output

2

Articles

2

WoS Citation Count

0

Scopus Citation Count

0

Scholarly Output Search Results

Now showing 1 - 2 of 2
  • Article
    Post Challenge Effects of Ozg-38.61.3 Gamma Irradiated SARS-CoV Vaccine on Organ Protection in Transgenic Mouse Model
    (Marmara University, Institute of Health Sciences, 2025) Telci, Dilek; Akpınar, Gürler; Tuğlu, Mehmet İbrahim; Ovalı, Ercüment; Oztatlıcı, Hulya; Şahin, Fikrettin; Demir, Sevda; Kancagi, Derya Dilek; Turan, Raife Dilek; Oztatlici, Mustafa; Karakus, Gozde Sir; Yurtsever, Bulut; Yalçın, Gözde
    Objective: Coronavirus disease 2019 (COVID-19) is an infectious outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) and virus-related deaths are increasing day by day. For this reason, vaccine studies and their urgent use are of great importance to prevent the pandemic. In this study, multi-organ damages caused by SARS-CoV-2 virus in human- angiotensin-converting enzyme type 2 (ACE2) transgenic mice and the protective effects of OZG-38.61.3 gamma irradiated SARS-CoV-2 vaccine against viral damage were investigated. Methods: For this purpose, transgenic K18-hACE2 BALB/c mice were randomly allocated into 4 groups, negative control group (NC), positive control group (PC, SARS-CoV-2 infected), and 2 different doses of OZG-38.61.3 vaccine (Challenge 1, dose of 10 13 and Ch2, 10 14 viral particle after SARS-CoV-2 infection). After the administrations, lung, heart and kidney tissues were examined by histopathological, immunohistochemical and TUNEL analysis. Results: Our results showed that the vaccine doses decreased the apoptosis, oxidative stress and inflammation parameters caused by virus in lung, heart, and kidney tissues. It was also found that the vaccine protected the expressions of tight junction proteins in the kidneys. Conclusion: According to our findings, it is suggested that the OZG-38.61.3 can be an effective and protective vaccine that can be safely used against the SARS-CoV-2 virus.
  • Article
    Dornaz Alfa'nın SARS-CoV-2 İçin Potansiyel Bir Tedavi Seçeneği Olarak Kullanımı: İn Vitro Bulgular
    (Society of Pharmaceutical Sciences of Ankara (FABAD), 2026) Büyükçolak, Yaren; Taştan, Cihan; Akyöney, Didem Çakırsoy; Karadeni̇z, Kevser Buse; Çakirsoy, Didem; Abanuz, Selen; Ovali, Ercüment; Kançağı, Derya Dilek; Dilek Kançaği, Derya
    The potential use of dornase alfa (DA) for managing severe acute respiratory syndrome coronavirus 2 infection has been a topic of frequent discussion; however, its underlying mechanism of effectiveness remains insufficiently explored. By shedding light on the mechanisms involved, this research endeavors to contribute to the broader understanding of DA's suitability as a potential treatment option for SARS-CoV-2 infection. In this study, the effects of DA on SARS-CoV-2 were investigated to determine the change in the level of viral cytotoxicity, viral RNA fragmentation, spike blockage, in vitro Th1/Th2 cytokine ratio of viral peptide stimulated lymphocytes and netosis Neutrophil extracellular traps formation. The analysis demonstrated that DA decreased the viral cytotoxicity at 30U (p